Phage Directory Phage Directory
Community↗

Jobs

↗

14 jobs

  • Master 2 internship in marine viral ecology and bioinformatics — BEEP, Plouzané (France)
  • PhD position in bacteria and materials interactions: living hydrogels with phages and probiotics for wound infections — Biointerfaces Laboratory, Empa (St. Gallen)

Events

↗

22 upcoming

  • Phage Across One Health SymposiumOct 30, 2026

Phage alerts

↗

71 alerts

Podovirus
Ep 18: Discussion of Phage Therapy for CF Patients - Rebekah Dedrick

Capsid & Tail

↗
  • Q&A: Favorite phage production equipment

    Issue 323Jessica Sacher

News

↗

231 news items

  • Tulane Ventures invests $250,000 in Biophoundry to advance engineered phage therapies

Updates

↗

12 updates

  • Phage prohead proteases activate CBASS antiphage immunity (Science)

Where to get Phage Therapy

↗

Treatment centers, clinical trials and next steps

Learn how phage therapy works, find programs around the world, and explore questions to discuss with your care team.

Communities Societies, networks and training groups Opportunities Funding, grants and fellowships Authors 142 contributors
Send a tip or feedback Write for Capsid & Tail

Search

Find articles, people and resources across Phage Directory.

Search Phage Directory…

8,013 results

  1. Therapy studies

    Bacteriophage Therapy in Patients With Prosthetic Joint Infections (PJI)

    Withdrawn. Checked 2026-10-03. This is a study designed to evaluate bacteriophage therapy in patients with chronic prosthetic joint infections. A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Eff

    ProstheticJointKneeHipPhageBacteriophageProsthetic JointDAIR
  2. Therapy studies

    PrePhage - Faecal Bacteriophage Transfer for Enhanced Gastrointestinal Tract Maturation in Preterm Infants

    Recruiting. Checked 2026-10-03. PrePhage - Fecal bacteriophage transfer for enhanced gastrointestinal tract maturation in preterm infants This pilot triol has the primary goal of demonstrating the safety of transferring viruses and protein

  3. Therapy studies

    A Study Investigating the Safety, Recovery, and Pharmacodynamics of Multiple Oral Administrations of SNIPR001 in Healthy Subjects

    Completed. Checked 2026-10-03. This is a Phase 1, randomized, double-blind, placebo-controlled, multiple dose, dose escalation study in healthy participants, investigating the safety, tolerability, recovery, and PD of multiple oral administ

  4. Therapy studies

    Mayo Clinic Phage Program Biobank

    Invitation only. Checked 2026-10-03. The purpose of this study is to help scientists and clinicians discover answers to research questions related to antibiotic-resistant bacterial infections, and the role that phage therapy plays as a poss

  5. Therapy studies

    Phage Therapy in Prosthetic Joint Infection Due to Staphylococcus Aureus Treated With DAIR.

    Ended. Checked 2026-10-03. Pilot non comparative study assessing the clinical control of infection of DAIR + SAT +NaCl and DAIR + SAT + Phages anti-Staphylococcus aureus in patients with Staphylococcus aureus Prosthetic Joint Infection with

    Joint InfectionStaphylococcus aureusPhagotherapy
  6. Therapy studies

    A Phase 1b/2 Trial of the Safety and Microbiological Activity of Bacteriophage Therapy in Cystic Fibrosis Subjects Colonized With Pseudomonas Aeruginosa

    Completed. Checked 2026-10-03. This is a phase 1b/2 study of a single dose of intravenous (IV) bacteriophage in males and non-pregnant females, at least 18 years old, diagnosed with Cystic Fibrosis (CF). This clinical trial is designed to a

    Bacteriophage therapycolonizedCystic Fibrosisdouble-blindMicrobiological Activityplacebo-controlledPseudomonas aeruginosarandomizedSafety
  7. Therapy studies

    A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)

    Recruiting. Checked 2026-10-03. This is a Phase 2 superiority study of LBP-EC01, a recombinant bacteriophage cocktail, with an initial open-label 3-arm pharmacokinetic (PK) lead-in portion of 30 patients to evaluate the optimal dosing regim

    LBP-EC01Urinary tract infectionE. coliBacteriophagePhagecrPhageRecombinant bacteriophage
  8. Therapy studies

    Bacteriophage Therapy of Difficult-to-treat Infections

    Completed. Checked 2026-10-03. A retrospective, observational analysis of the first one hundred consecutive cases of bacteriophage therapy of difficult-to-treat infections, facilitated by a Belgian consortium. Bacteriophage Therapy of Diffi

    Bacterial infectionsBacteriophagesAntibiotic resistanceObservational studyRetrospective analysisDifficult to treat infections
  9. Therapy studies

    Phage Therapy for the Treatment of Urinary Tract Infection

    Status unconfirmed. Individual-case protocol. Checked 2026-10-03. This is a single-patient, phase I/II clinical trial that aims to evaluate the potential of bacteriophage therapy to treat and prevent the recurrence of a drug-resistant urina

    Phage TherapyRecurrent urinary tract infection
  10. Therapy studies

    Effect of PreforPro® on Urinary and Vaginal Health

    Status unconfirmed. Checked 2026-10-03. This study will investigate the effects of PreforPro® (prebiotic and bacteriophages (LH01-Myoviridae, LL5-Siphoviridae, T4D-Myoviridae, and LL12-Myoviridae, greater > 6.7 X 107 PFU/gram) on bacterial

  11. Therapy studies

    Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection

    Completed. Checked 2026-10-03. A phase 2, multi-center, double-blind, randomized, placebo-controlled study to evaluate the safety, phage kinetics, and efficacy of inhaled AP-PA02 administered in subjects with non-cystic fibrosis bronchiecta

    BacteriophagePhageNCFBBEPseudomonasPseudomonas Aeruginosa
  12. Therapy studies

    Safety and Efficacy of Oral Administration of the Phage Cocktail, VRELysin™, In Healthy and VRE-Colonized Subjects

    Suspended. Checked 2026-10-03. The study is a first-in-human Phase 1/2a randomized, double-blind, placebo-controlled trial to assess the clinical safety and efficacy of VRELysin in healthy and VRE-colonized adults. A Phase 1/2a Double-Blind

    bacteriophagephageVREEnterococcusvancomycin
  13. Therapy studies

    Phage 3Determination of Phage/Probiotic Synergistic Effects on Gastrointestinal Health

    Completed. Checked 2026-10-03. The goal of this double blinded clinical trial is to determine whether consumption of the PreforPro product, when co-consumed with Bacillus subtilis DE111 probiotic, synergistically improves bowel regularity,

    PreforProProbioticsBacillus subtilisPrebioticsGut healthGut microbiotaSynergistic effects
  14. Therapy studies

    Avis-PHAGEinLYON Clinic

    Recruiting. Checked 2026-10-03. Avis-PHAGEinLYON Clinic study is a single site non-interventional retrospective and prospective study, initiated by the Hospices Civils de Lyon. Population targeted are patients referred to the Hospices Civil

    bacteriophagemedical advice
  15. Therapy studies

    Bacteriophage Therapy TP-102 in Patients With Diabetic Foot Infection

    Completed. Checked 2026-10-03. TP-102 is a novel bacteriophage cocktail comprised of 5 (five) lytic bacteriophages against Staphylococcus aureus, Pseudomonas aeruginosa, and Acinetobacter baumannii. TP-102 is being developed for topical tre

  16. Therapy studies

    Treatment Chronic UTI Post Kidney Transplant

    Terminated. Checked 2026-10-03. Urinary tract infections (UTIs) with extended-spectrum -lactamase (ESBL)-positive Enterobacteriums (ESBL-E) are a common infectious complication of renal transplant recipients, with 10% of patients suffering

  17. Therapy studies

    Clinical Study of Phage Therapy for Chronic Constipation Efficacy and Safety

    Status unconfirmed. Checked 2026-10-03. The overall aim was to evaluate the efficacy of PiB-specific phages for the treatment of refractory constipation through clinical studies, primarily for the publication of scientific papers and to gui

  18. Therapy studies

    PHAGEinLYON Clinic Cohort Study: a Descriptive Study of Severe Infections Treated With Phage Therapy at the HCL.

    Recruiting. Checked 2026-10-03. PHAGEinLYON Clinic cohort study is a single site non-interventional retrospective and prospective study, initiated by the Hospices Civils de Lyon. Population targeted are patients with a severe infection trea

    bacteriophagesevere infection
  19. Therapy studies

    Mycobacteriophage Treatment of Non-tuberculosis Mycobacteria

    Invitation only. Checked 2026-10-03. About 10 people with cystic fibrosis (CF) and persistent Nontuberculosis mycobacteria (NTM) infection despite treatment will be screened to find out if their NTM infection has at least one mycobacterioph

    cystic fibrosisphagemycobacteriophage
  20. Therapy studies

    First-in-man Single-dose and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy ofHY-133

    Recruiting. Checked 2026-10-03. In this clinical trial we will test a new approach for decolonization of S. aureus. As innovative product HY-133 a recombinant chimeric bacteriophage endolysin will be sprayed in both nostrils of healthy sub

Previous Page 399 of 401 Next

Supported by

Mozilla The Leona M. and Harry B. Helmsley Charitable TrustThe Leona M. and Harry B. Helmsley Charitable Trust

Phage Directory

hello@phage.directory
@phagedirectory

Learn how we use AI in our writing, research and site development. Read more.

Capsid & Tail

Latest issue All issues Authors Podovirus RSS feed

Phage Directory

About Send a tip Community Communities Updates News Jobs Events Opportunities Where to get Phage Therapy Phage alerts